Breadcrumbs

Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP)

Pre-exposure prophylaxis (PrEP) for HIV is the newest HIV prevention strategy. PrEP is the use of antiretroviral medications to prevent HIV transmission. Clinical trials from around the world have demonstrated the safety and efficacy of PrEP at reducing HIV transmission among people at high-risk of acquiring HIV.

Accessing PrEP

Medications for PrEP were approved by the Therapeutic Goods Administration (TGA) in Australia in 2016, however, they are not approved for subsidy by the Pharmaceutical Benefits Advisory Committee for use as HIV PrEP. South Australians with a prescription for PrEP from an S100 prescriber may either purchase PrEP in Australia or overseas for personal use under the TGA’s personal importation scheme. Alternately, South Australians may access PrEP for HIV by enrolling in the PrEPX-SA access trial.

PrEPX-SA access trial

PrEPX-SA is an access trial funded by the Government of South Australia. The trial is monitoring access to PrEP medication for eligible people and its impact on the rate of new HIV infections across the state. PrEPX-SA is open to 500 South Australians at high-risk of acquiring HIV. The trial will run until 30 June 2018.

PrEPX-SA is being delivered by the South Australian Health and Medical Research Institute (SAHMRI) in partnership with Alfred Health Victoria and Adelaide metropolitan health clinics including: 

PrEPX-SA is an extension of the Victorian PrEPX trial. Both PrEPX and PrEPX-SA have received research ethics approval through the Alfred Health Human Research Ethics Committee.

For more information about the trial, please visit Alfred Health’s PrEPX-SA webpage.

Further information

Clinicians

Consumers

 

^ Back to top